Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a group of antidiabetic medications with a favourable cardiovascular, renal and overall safety profile. Given the limited treatment options available for neurological disorders, it is important to determine whether the pleiotropic ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Tharmaraja, Thahesh, Ho, Jamie S.Y., Sia, Ching-Hui, Lim, Nicole-Ann, Chong, Yao Feng, Lim, Amanda Y.L., Rathakrishnan, Rahul R., Yeo, Leonard L.L., Sharma, Vijay K., Tan, Benjamin Y.Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006360/
https://www.ncbi.nlm.nih.gov/pubmed/35432846
http://dx.doi.org/10.1177/20406223221086996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006360/
https://www.ncbi.nlm.nih.gov/pubmed/35432846
http://dx.doi.org/10.1177/20406223221086996

Ejemplares similares